𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CHOP and COPBLAM chemotherapy for diffuse large cell non-Hodgkin's lymphomas: A retrospective comparison

✍ Scribed by Heinrich H. Gerhartz; Eckhard Thiel; Erhard Hiller; Christoph Nerl; Hans J. Kolb; Wolfgang Wilmanns; Dieter Huhn


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
421 KB
Volume
6
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis


Between 1979 and 1985 61 consecutive patients with non-Hodgkin's lymphomas of unfavourable histology (mostly diffuse large cell lymphomas subclassified according to Kiel nomenclature) were treated in our departments by either the CHOP-(n = 34) or the COPBLAM-regimen (n = 27). A retrospective analysis revealed that prognostic variables, excluding primary central nervous system (CNS)-involvement (n = 5), were equally distributed between both groups. Remission rates were significantly higher in the COPBLAM treated patients as compared with the CHOP treated group (85 per cent versus 38 per cent CR, P= 0.001) even when cases with primary CNS-disease were excluded. The survival curve did not reach a plateau in CHOP treated cases, whereas 85 per cent of the COPBLAM treated group reached a plateau by 15 months. The mean observation time, however, was shorter in the COPBLAM treated group (37 versus 30 months, respectively).

It is concluded that the COPBLAM regimen is superior to the CHOP-protocol in inducing complete responses in aggressive non-Hodgkin's lymphomas. Longer follow-ups are needed to definitely show if this corresponds to an increased proportion of 'cures'.


πŸ“œ SIMILAR VOLUMES


Prognostic factors for patients with dif
✍ Simon, Richard ;Durrleman, Sylvain ;Hoppe, Richard T. ;Bonadonna, Gianni ;Bloomf πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 678 KB

## Abstract Prognostic factors for long‐term survival of 312 patients with diffuse large cell or immunoblastic non‐Hodgkin's lymphoma are presented based on analysis of the multi‐institution clinicopathologic study sponsored by the National Cancer Institute. At the time of analysis, 75% of the pati

Multicentre combined chemotherapy protoc
✍ J. Dumont; P. Charpy-Validire; V. Mosseri; J. Gabarre; C. Belanger; F. Turpin; J πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 702 KB

## Abstract Between October 1985 and October 1989, 75 previously untreated patients with stage III and IV non Hodgkin's lymphoma, large cell type, were treated with an alternating weekly chemotherapy regimen including the following drugs: week 1: Doxorubicin, vincristine, cyclophosphamide, bleomyci